• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

尼日利亚 2 型糖尿病患者血糖控制与非酒精性脂肪肝的关系。

The Relationship Between Glycaemic Control and Non-Alcoholic Fatty Liver Disease in Nigerian Type 2 Diabetic Patients.

机构信息

Department of Radiology, Obafemi Awolowo University (OAU)/OAU Teaching Hospitals Complex, Ile Ife, Nigeria.

Department of Internal Medicine, Obafemi Awolowo University (OAU)/ OAU Teaching Hospitals Complex, Ile Ife, Nigeria.

出版信息

J Natl Med Assoc. 2018 Jun;110(3):256-264. doi: 10.1016/j.jnma.2017.06.001. Epub 2017 Jun 27.

DOI:10.1016/j.jnma.2017.06.001
PMID:29778128
Abstract

BACKGROUND

Metabolic risk factors associated with non-alcoholic fatty liver disease (NAFLD) include Type 2 diabetes mellitus (T2DM), obesity and dyslipidaemia. Prevention or management of these risk factors with glycaemic control, weight reduction and low serum lipid levels respectively have been reported to reduce the risk of NAFLD or slow its progression. Since ultrasound (USS) is a safe and reliable method of identifying fatty changes in the liver, this study was done to determine the relationship between glycaemic control and ultrasound diagnosed NAFLD in T2DM.

METHODOLOGY

Demographic data, anthropometric measurements and laboratory tests including glycated haemoglobin (HbA1c), fasting blood glucose (FBG) and serum lipids of 80 T2DM subjects aged 40-80 years were taken. Their livers were evaluated using B-mode ultrasound, and the data obtained were statistically analysed using SPSS version 20.

RESULTS

Fifty-five of all participants (68.8%) were diagnosed with NAFLD sonographic grades 1, 2 and 3 made up of 13 (16.3%), 26 (32.5%) and 16 (20.0%), respectively while 25 (37.2%) had grade 0. The prevalence of NAFLD in T2DM varied significantly with BMI (p = 0.001) and glycaemic control (p = 0.048) while the USS grades of NAFLD varied significantly with age (p = 0.043) and BMI (p = 0.006). The independent strong predictors of NAFLD were overweight (r = 0.409, p = 0.012, OR = 6.626) and obesity (r = 0.411 p = 0.009, OR = 11.508), while poor glycaemic control (r = 0.270, p = 0.015, OR = 3.473) was a moderate independent predictor.

CONCLUSION

The prevalence of NAFLD increases with increasing BMI and HBA1c in T2DM, while its ultrasound grade varies with BMI. Overweight, obesity and poor glycaemic control are independent predictors of NAFLD.

摘要

背景

与非酒精性脂肪肝(NAFLD)相关的代谢风险因素包括 2 型糖尿病(T2DM)、肥胖和血脂异常。分别通过血糖控制、体重减轻和血清脂质水平来预防或管理这些风险因素,据报道可降低 NAFLD 的风险或减缓其进展。由于超声(USS)是一种安全可靠的方法,可以识别肝脏的脂肪变化,因此进行了这项研究,以确定 T2DM 中血糖控制与超声诊断的 NAFLD 之间的关系。

方法

收集 80 名年龄在 40-80 岁的 T2DM 患者的人口统计学数据、人体测量学测量值和实验室检查结果,包括糖化血红蛋白(HbA1c)、空腹血糖(FBG)和血清脂质。使用 B 模式超声评估他们的肝脏,并使用 SPSS 版本 20 对获得的数据进行统计分析。

结果

所有参与者中有 55 人(68.8%)被诊断为超声分级 1、2 和 3 的 NAFLD,分别为 13 人(16.3%)、26 人(32.5%)和 16 人(20.0%),而 25 人(37.2%)为 0 级。T2DM 中 NAFLD 的患病率与 BMI(p=0.001)和血糖控制(p=0.048)显著相关,而 NAFLD 的 USS 分级与年龄(p=0.043)和 BMI(p=0.006)显著相关。NAFLD 的独立强预测因素是超重(r=0.409,p=0.012,OR=6.626)和肥胖(r=0.411,p=0.009,OR=11.508),而血糖控制不佳(r=0.270,p=0.015,OR=3.473)是中度独立预测因素。

结论

T2DM 中,NAFLD 的患病率随 BMI 和 HBA1c 的增加而增加,而其超声分级则随 BMI 而变化。超重、肥胖和血糖控制不佳是 NAFLD 的独立预测因素。

相似文献

1
The Relationship Between Glycaemic Control and Non-Alcoholic Fatty Liver Disease in Nigerian Type 2 Diabetic Patients.尼日利亚 2 型糖尿病患者血糖控制与非酒精性脂肪肝的关系。
J Natl Med Assoc. 2018 Jun;110(3):256-264. doi: 10.1016/j.jnma.2017.06.001. Epub 2017 Jun 27.
2
Obesity and metabolic syndrome as risk factors for the development of non-alcoholic fatty liver disease as diagnosed by ultrasound.肥胖和代谢综合征作为通过超声诊断的非酒精性脂肪性肝病发生的风险因素。
Vojnosanit Pregl. 2016 Oct;73(10):910-20. doi: 10.2298/VSP150514093P.
3
Comparison of effects of obesity and non-alcoholic fatty liver disease on incidence of type 2 diabetes mellitus.肥胖与非酒精性脂肪性肝病对2型糖尿病发病率影响的比较。
World J Gastroenterol. 2015 Aug 28;21(32):9607-13. doi: 10.3748/wjg.v21.i32.9607.
4
Non alcoholic fatty liver disease in a Nigerian population with type II diabetes mellitus.尼日利亚II型糖尿病患者中的非酒精性脂肪性肝病
Pan Afr Med J. 2016 May 6;24:20. doi: 10.11604/pamj.2016.24.20.8181. eCollection 2016.
5
Prevalence of nonalcoholic fatty liver disease and liver cirrhosis in Chinese adults with type 2 diabetes mellitus.中国 2 型糖尿病患者中非酒精性脂肪性肝病和肝硬化的患病率。
J Diabetes. 2024 May;16(5):e13564. doi: 10.1111/1753-0407.13564.
6
Increased risks of different grades of non-alcoholic fatty liver disease in prediabetic subjects with impaired fasting glucose and glucose tolerance, including the isolated glycosylated hemoglobin levels of 5.7-6.4% in a Chinese population.在中国人群中,空腹血糖受损和糖耐量受损的糖尿病前期患者,即使糖化血红蛋白水平为 5.7%-6.4%,也会增加不同程度非酒精性脂肪性肝病的发病风险。
J Diabetes Investig. 2020 Sep;11(5):1336-1343. doi: 10.1111/jdi.13268. Epub 2020 May 17.
7
Serum Ferritin level, microalbuminuria and non-alcoholic fatty liver disease in type 2 diabetic patients.2型糖尿病患者的血清铁蛋白水平、微量白蛋白尿与非酒精性脂肪性肝病
Diabetes Metab Syndr. 2019 May-Jun;13(3):2226-2229. doi: 10.1016/j.dsx.2019.05.030. Epub 2019 May 25.
8
Association of non-alcoholic fatty liver disease with total testosterone in non-overweight/obese men with type 2 diabetes mellitus.非超重/肥胖 2 型糖尿病男性患者非酒精性脂肪性肝病与总睾酮的相关性。
J Endocrinol Invest. 2023 Aug;46(8):1565-1572. doi: 10.1007/s40618-023-02006-6. Epub 2023 Feb 1.
9
Nonalcoholic fatty liver disease and microvascular complications in type 2 diabetes.非酒精性脂肪性肝病与 2 型糖尿病的微血管并发症。
World J Gastroenterol. 2013 May 28;19(20):3134-42. doi: 10.3748/wjg.v19.i20.3134.
10
Relationship between glycaemic control and lipid profile in type 2 diabetes mellitus patients in a low-resource setting.在资源匮乏环境下,2 型糖尿病患者的血糖控制与血脂特征之间的关系。
Pan Afr Med J. 2022 Apr 7;41:281. doi: 10.11604/pamj.2022.41.281.33802. eCollection 2022.

引用本文的文献

1
Association between glucose time-in-range and the severity of metabolic dysfunction-associated steatotic liver disease in Chinese adults with type 2 diabetes mellitus.中国2型糖尿病成年患者血糖在目标范围内的时间与代谢功能障碍相关脂肪性肝病严重程度之间的关联
BMC Endocr Disord. 2025 Apr 23;25(1):113. doi: 10.1186/s12902-025-01937-w.
2
Association of non-alcoholic fatty liver disease with glycemic control among patients with type 2 diabetes mellitus at Limbe Regional Hospital, Southwest, Cameroon.喀麦隆西南部林贝地区医院2型糖尿病患者中非酒精性脂肪性肝病与血糖控制的关联
World J Hepatol. 2025 Feb 27;17(2):101936. doi: 10.4254/wjh.v17.i2.101936.
3
NON-ALCOHOLIC FATTY LIVER DISEASE AND RELATIONSHIP WITH ADIPOSITY IN NIGERIAN PATIENTS WITH TYPE 2 DIABETES MELLITUS: THE IBADAN EXPERIENCE.
尼日利亚2型糖尿病患者的非酒精性脂肪性肝病及其与肥胖的关系:伊巴丹经验
Ann Ib Postgrad Med. 2024 Aug 30;22(2):74-80.
4
Impact of Sodium-Glucose Co-Transporter Type-2 Inhibitors on Alanine Aminotransferase Levels in Type-2 Diabetes Patients Having Features of Nonalcoholic Fatty Liver Disease: A Retrospective Cohort Study in Pakistan.2型钠-葡萄糖协同转运蛋白抑制剂对具有非酒精性脂肪性肝病特征的2型糖尿病患者丙氨酸氨基转移酶水平的影响:巴基斯坦的一项回顾性队列研究
Pak J Med Sci. 2024 Dec;40(11):2681-2688. doi: 10.12669/pjms.40.11.8900.
5
Prevalence of metabolic dysfunction-associated fatty liver disease and its association with glycemic control in persons with type 2 diabetes in Africa: A systematic review and meta-analysis.非洲2型糖尿病患者中代谢功能障碍相关脂肪性肝病的患病率及其与血糖控制的关联:一项系统评价和荟萃分析
PLOS Glob Public Health. 2024 May 6;4(5):e0002835. doi: 10.1371/journal.pgph.0002835. eCollection 2024.
6
The interplay between diabetes and non-alcoholic fatty liver disease: a cross-sectional study from Pakistan.糖尿病与非酒精性脂肪性肝病之间的相互作用:一项来自巴基斯坦的横断面研究。
Ann Med Surg (Lond). 2024 Feb 28;86(4):1929-1932. doi: 10.1097/MS9.0000000000001875. eCollection 2024 Apr.
7
Fatty liver biomarkers and insulin resistance indices in the prediction of non-alcoholic fatty liver disease in Ghanaian patients.加纳患者中脂肪肝生物标志物和胰岛素抵抗指数对非酒精性脂肪肝的预测价值。
Endocrinol Diabetes Metab. 2023 Nov;6(6):e456. doi: 10.1002/edm2.456. Epub 2023 Oct 9.
8
Association between dietary glycemic index and non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus.膳食血糖生成指数与 2 型糖尿病患者非酒精性脂肪肝的相关性。
Front Endocrinol (Lausanne). 2023 Aug 22;14:1228072. doi: 10.3389/fendo.2023.1228072. eCollection 2023.
9
Pharmaceutical Strategies to Improve Druggability of Potential Drug Candidates in Nonalcoholic Fatty Liver Disease Therapy.改善非酒精性脂肪性肝病治疗中潜在候选药物成药性的药学策略。
Pharmaceutics. 2023 Jul 16;15(7):1963. doi: 10.3390/pharmaceutics15071963.
10
New anti-diabetic agents for the treatment of non-alcoholic fatty liver disease: a systematic review and network meta-analysis of randomized controlled trials.新型抗糖尿病药物治疗非酒精性脂肪性肝病:随机对照试验的系统评价和网络荟萃分析。
Front Endocrinol (Lausanne). 2023 Jun 27;14:1182037. doi: 10.3389/fendo.2023.1182037. eCollection 2023.